Latest Institutional Shareholding News

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Basin Energy secures A$1.1 million through a strategic placement led by two uranium-sector investors, aiming to accelerate drilling and geophysics at its Sybella Barkly and Newmans projects in Queensland.

4DMedical lands a contract with pharma giant GSK, gains UKCA certification for its CT:VQ™ lung imaging technology, and joins the S&P/ASX 200, marking a significant step in its global expansion.

AuMEGA Metals has closed a C$30.1 million financing round, bolstering its institutional shareholder base and fully funding an expanded 2026 exploration program across its Newfoundland projects.

Tamboran Resources Corporation has secured up to US$198 million through a combination of public and entitlement offers to fund expanded drilling and resource delineation in the Beetaloo Basin, aiming for first gas sales by Q3 2026.

Syrah Resources has successfully closed its institutional entitlement offer, securing A$44 million at a share price of 10.5 cents, with the retail offer now open to shareholders. This capital raise aims to strengthen the company’s financial position as it advances its graphite and anode material operations.

Australian Vanadium Limited has raised $7.5 million through a targeted placement to accelerate its vertically integrated vanadium strategy, including the Kalgoorlie battery energy storage project.

AuMEGA Metals has launched a C$10 million private placement to fund an extensive drilling program targeting high-potential gold and base metal prospects in Newfoundland’s Cape Ray District. The financing aims to unlock value from its significant mineral resources and strategic landholdings.

PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

Benz Mining Corp. has raised A$75 million through a bought deal placement, significantly strengthening its cash reserves to nearly A$94 million. This capital injection will accelerate exploration and resource development at its Glenburgh and Mt Egerton Gold Projects in Western Australia.

29Metals has successfully closed its institutional entitlement offer, raising approximately $119 million at a notable discount, with a retail offer set to launch later this month. The capital raise aims to fuel key growth projects across its mining portfolio.